Meningococcal vaccine Men Quardfi has been approved by the European Union

Meningitis Nesser is the main cause of bacterial meningitis and sepsis.
most commonly occurs in the "meningitis belt" of sub-Saharan Africa.
have a high fatality rate for invasive meningococcal disease (50 per cent, if left untreated) and many survivors have permanent sequelae.
A, B, C, X, W and Y are the main causes of the disease in 12 identified meningitis nessella.
, MenacWY vaccine Men Quardfi, a French pharmaceutical company, has been approved by the European Union (EC).
MenQuadfi actively immunized individuals over 12 months against invasive meningococcal disease caused by meningococcal A, C, W and Y serotypes.
the approval is based on the Sanofi Men Quudi International Clinical Program, which includes seven Phase II and III studies.
the Sanofi vaccine with all other vaccines on the market, proving that MenQuadfi is safe and producing a high immune response to all four serotypes throughout the study.
Triomphe, head of Sanofi Pasteur, said: "Meningococcal disease can take lives in just one day and leave survivors with severe permanent disabilities.
in Europe, there were 3,000 cases of invasive meningococcal disease in 2018, half of which were caused by Serotypes C, W and Y".
。